{"database": "openregs", "table": "congressional_record", "rows": [["CREC-2026-02-26-pt1-PgS711-2", "2026-02-26", 119, 2, null, null, "SENATE RESOLUTION 620--DESIGNATING FEBRUARY 28, 2026, AS \"RARE DISEASE DAY\"", "SENATE", "SENATE", "DESIGNATING", "S711", "S711", null, "[{\"congress\": \"119\", \"type\": \"SRES\", \"number\": \"620\"}, {\"congress\": \"119\", \"type\": \"SRES\", \"number\": \"620\"}, {\"congress\": \"119\", \"type\": \"SRES\", \"number\": \"620\"}]", "172 Cong. Rec. S711", "Congressional Record, Volume 172 Issue 38 (Thursday, February 26, 2026)\n\n[Congressional Record Volume 172, Number 38 (Thursday, February 26, 2026)]\n[Senate]\n[Page S711]\nFrom the Congressional Record Online through the Government Publishing Office [www.gpo.gov]\n\nSENATE RESOLUTION 620--DESIGNATING FEBRUARY 28, 2026, AS ``RARE DISEASE\n                                 DAY''\n\n  Mr. BARRASSO (for himself and Mr. Blumenthal) submitted the following\nresolution; which was considered and agreed to:\n\n                              S. Res. 620\n\n       Whereas a rare disease or disorder is a disease or disorder\n     that affects a small number of patients;\n       Whereas, in the United States, a rare disease or disorder\n     is defined as affecting fewer than 200,000 individuals;\n       Whereas, as of the date of adoption of this resolution,\n     more than 30,000,000 individuals in the United States are\n     living with at least 1 of the more than 10,000 known rare\n     diseases or disorders;\n       Whereas children with rare diseases or disorders account\n     for a significant portion of the population affected by rare\n     diseases or disorders in the United States;\n       Whereas many rare diseases and disorders are serious and\n     life-threatening;\n       Whereas financing life-altering and lifesaving treatments\n     can be challenging for individuals with a rare disease or\n     disorder and their families;\n       Whereas individuals with rare diseases or disorders can\n     experience difficulty in obtaining accurate diagnoses and\n     finding physicians or treatment centers with expertise in\n     their rare disease or disorder;\n       Whereas, although there have been great advancements in\n     finding treatments for rare diseases, approximately 95\n     percent of rare diseases still do not have a treatment\n     approved by the FDA;\n       Whereas 2026 marks the 43rd anniversary of the enactment of\n     the Orphan Drug Act (Public Law 97-414; 96 Stat. 2049), a\n     landmark law enabling tremendous advances in the research and\n     treatment of rare diseases and disorders;\n       Whereas the National Institutes of Health support\n     innovative research on the treatment of rare diseases and\n     disorders;\n       Whereas programs such as the Accelerating Rare disease\n     Cures Program of the Food and Drug Administration (referred\n     to in this preamble as the ``FDA'') aim to drive scientific\n     and regulatory innovation and engagement to accelerate the\n     availability of treatments for patients with rare diseases;\n       Whereas 23 of the 46 novel drugs approved by the Center for\n     Drug Evaluation and Research of the FDA in 2025--\n       (1) were approved to prevent, diagnose, or treat a rare\n     disease or condition; and\n       (2) received an orphan-drug designation;\n       Whereas Rare Disease Day is observed each year on the last\n     day of February; and\n       Whereas Rare Disease Day is a global event that was first\n     observed in the United States on February 28, 2009: Now,\n     therefore, be it\n       Resolved, That the Senate--\n       (1) designates February 28, 2026, as ``Rare Disease Day'';\n     and\n       (2) recognizes the importance of, with respect to rare\n     diseases and disorders--\n       (A) improving awareness;\n       (B) encouraging accurate and early diagnosis; and\n       (C) supporting national and global research efforts to\n     develop effective treatments, diagnostics, and cures.\n\n                          ____________________"]], "columns": ["granule_id", "date", "congress", "session", "volume", "issue", "title", "chamber", "granule_class", "sub_granule_class", "page_start", "page_end", "speakers", "bills", "citation", "full_text"], "primary_keys": ["granule_id"], "primary_key_values": ["CREC-2026-02-26-pt1-PgS711-2"], "units": {}, "query_ms": 47.90526698343456, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}